Page 75 - Read Online

Cordero et al. Vessel Plus 2017;1:68-76 Vessel Plus
DOI: 10.20517/2574-1209.2017.02
www.vpjournal.net
Original Article Open Access

Initial experience with bioresorbable vascular

scaffolds for percutaneous revascularisation

in patients with acute coronary syndrome

Alberto Cordero, Ramón López-Palop, Pilar Carrillo, Araceli Frutos, Clara Gunturiz, Maria García-Carrilero,
Vicente Bertomeu-Martinez

Department of Cardiology, Hospital Universitario de San Juan, Alicante 03540, Spain.

Correspondence to: Dr. Alberto Cordero, Department of Cardiology, Hospital Universitario de San Juan, Alicante 03540, Spain.
E-mail: acorderofort@gmail.com
How to cite this article: Cordero A, López-Palop R, Carrillo P, Frutos A, Gunturiz C, García-Carrilero M, Bertomeu-Martinez V. Initial experience with
bioresorbable vascular scaffolds for percutaneous revascularisation in patients with acute coronary syndrome. Vessel Plus 2017;1:68-76.

ABSTRACT
Article history: Aim: Bioresorbable vascular scaffolds (BVS) have recently been introduced to minimise
Received: 21-01-2017 the long-term complications of metallic stents in acute coronary syndrome (ACS), but
Accepted: 22-03-2017 their benefits have not been well analysed. Methods: The authors studied all ACS patients
Published: 27-06-2017 treated with any kind of stent at a single centre between March 2013 (when the first BVS was
implanted) and June 2016. Results: The study included 951 subjects, mean age 67.9 ± 13.3
years, mean Global Registry of Acute Coronary Events (GRACE) score 148.5 ± 44.8, 75.2%
Key words: men and 38.2% with an ST-segment elevation myocardial infarction. The mean number of
Bioresorbable vascular stents, stents implanted was 1.3 ± 1.0 and 54 subjects (5.7%) received at least 1 BVS. Drug-eluting
stents, stents were implanted in 57.3% subjects, followed by bare-metal stents (19.0%). The subjects
acute coronary syndrome, treated with BVS were younger and had lower GRACE scores compared to the rest. In-
revascularisation, hospital mortality was 4.8% and no subject treated with BVS died before discharge. BVS-
prognosis treated patients received dual antiplatelet therapy or new antiplatelet agents more frequently.
During a median follow-up of 13 months, all-cause mortality was 7.8%, cardiovascular
mortality was 6.1%, and at least 1 major cardiovascular event occurred in 26.4% of the
subjects. Stent type did not affect prognosis. Conclusion: Coronary revascularisation using
BVS in selected ACS patients is safe and effective.

INTRODUCTION and intraluminal thrombosis that become manifest
as an acute coronary syndrome (ACS), ventricular
[2]
Cardiovascular disease is the leading cause of fibrillation, asystole, and sudden death. Percutaneous
mortality in the world, and coronary heart disease coronary interventions are the cornerstone of ACS
is the primary contributor to that cardiovascular treatment, and coronary stents are utilised in almost
[1]
mortality. Coronary heart disease is a progressive all of these. [3-5] Bare-metal stents (BMS) were the first
condition resulting from atherosclerosis that produces devices developed to improve the results of balloon
unstable coronary plaque, with episodes of erosion angioplasty by the resolving post-balloon dissections,

Quick Response Code:
This is an open access article licensed under the terms of Creative Commons Attribution 4.0 International
License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, as long as the original author is credited and the new creations are licensed under the
identical terms.
For reprints contact: service@oaepublish.com

68 © 2017 OAE Publishing Inc. www.oaepublish.com